This article provides an overview of a market research report from GlobeNewswire.
The biologics CDMO market is poised for robust growth in the coming years, driven by an expanding biologics pipeline and increasing demand for outsourcing. The market size is projected to reach $38.29 billion by 2031, up from $27.13 billion in 2026, with an estimated Compound Annual Growth Rate (CAGR) of 7.14% during the forecast period.
Report Overview
This report offers an in-depth analysis of the trends within the biologics development and manufacturing outsourcing market. It specifically focuses on fill-finish and packaging services, evaluating global demand drivers, strategies of key players, and regional growth opportunities.
Key Findings
- Market Growth Forecast: The biologics CDMO market is predicted to expand from $27.13 billion in 2026 to $38.29 billion by 2031, growing at a CAGR of 7.14%. This growth is propelled by the continuous increase in the biologics pipeline and the rising need to outsource complex manufacturing processes.
- Importance of Fill-Finish: Fill-finish and packaging services commanded a significant 34.96% share of the biologics CDMO market in 2025. This reflects the stringent sterility, quality, and regulatory requirements for final drug products, underscoring the strategic importance of this segment. Lonza’s investment of 500 million CHF (approximately 75 billion JPY) in a large-scale fill-finish facility in Switzerland clearly demonstrates CDMOs’ focus on this area.
- Major CDMO Contract Securing: Samsung Biologics has secured long-term manufacturing contracts worth $13 billion (approximately 1.9 trillion JPY) with major global pharmaceutical companies, indicating a strong demand for integrated development and production services. This highlights CDMOs’ indispensable role as partners for pharmaceutical companies.
- Impact of Regulatory Trends: The U.S. FDA’s guidance on continuous processes and expedited review pathways are encouraging the adoption of innovative manufacturing technologies at early stages, thereby stimulating market growth. Additionally, large-scale projects by pharmaceutical giants like Novo Nordisk are accelerating regional production capacity expansions.
- Regional Growth: The Asia-Pacific region is projected to be the fastest-growing market, driven by expanding production capabilities and government incentives. This suggests the region is increasingly playing a pivotal role in the global biopharmaceutical supply chain.
About the Publisher
GlobeNewswire is a leading provider of news release distribution services to companies, organizations, and government agencies worldwide. Market research reports distributed through its platform serve as critical resources for investors, analysts, and the media.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments